UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Membrane disrupting lytic peptides for cancer treatments

Current pharmaceutical design, 2004-01, Vol.10 (19), p.2299-2310

2004

Volltextzugriff (PDF)

Novel Use of Low-Dose Radiotherapy to Modulate the Tumor Microenvironment of Liver Metastases

Frontiers in immunology, 2021-12, Vol.12, p.812210-812210

2021

Volltextzugriff (PDF)

Combining a nanoparticle-mediated immunoradiotherapy with dual blockade of LAG3 and TIGIT improves the treatment efficacy in anti-PD1 resistant lung cancer

Journal of nanobiotechnology, 2022-09, Vol.20 (1), p.1-417, Article 417

2022

Volltextzugriff (PDF)

Inhibition of MER proto-oncogene tyrosine kinase by an antisense oligonucleotide enhances treatment efficacy of immunoradiotherapy

Journal of experimental & clinical cancer research, 2024-03, Vol.43 (1), p.70-70, Article 70

2024

Volltextzugriff (PDF)

NBTXR3 improves the efficacy of immunoradiotherapy combining nonfucosylated anti-CTLA4 in an anti-PD1 resistant lung cancer model

Frontiers in immunology, 2022-11, Vol.13, p.1022011-1022011

2022

Volltextzugriff (PDF)

Nanofabrication Towards Biomedical Applications: Techniques, Tools, Applications, and Impact

1, 2005

Volltextzugriff (PDF)

Molecular MRI for sensitive and specific detection of lung metastases

Proceedings of the National Academy of Sciences - PNAS, 2010-02, Vol.107 (8), p.3693-3697

2010

Volltextzugriff (PDF)

LHRH-conjugated magnetic iron oxide nanoparticles for detection of breast cancer metastases

Breast cancer research and treatment, 2006-09, Vol.99 (2), p.163-176

2006

Volltextzugriff (PDF)

Targeting Breast and Prostate Cancers Through Their Hormone Receptors

Biology of reproduction, 2005-11, Vol.73 (5), p.860-865

2005

Volltextzugriff (PDF)

Abstract LB-303: Novel peptide is synergistic with checkpoint inhibitor antiCTLA4

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.LB-303-LB-303

2018

Volltextzugriff (PDF)

Abstract 3199: Targeting LHRH-R to improve immune response in ovarian cancer

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.3199-3199

2019

Volltextzugriff (PDF)

A multicenter open-label randomized phase II trial of paclitaxel plus EP-100, a novel LHRH receptor-targeted, membrane-disrupting peptide, versus paclitaxel alone for refractory or recurrent ovarian cancer

Gynecologic oncology, 2021-02, Vol.160 (2), p.418-426

2021

Volltextzugriff (PDF)

Enhanced Immunotherapy with LHRH-R Targeted Lytic Peptide in Ovarian Cancer

Molecular cancer therapeutics, 2020-11, Vol.19 (11), p.2396-2406

2020

Volltextzugriff (PDF)

Abstract 978: Synergistic activity of EP-100 and chemotherapies in cancer cell lines

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.978-978

2013

Volltextzugriff (PDF)

Destruction of breast cancers and their metastases by lytic peptide conjugates in vitro and in vivo

Molecular and cellular endocrinology, 2007-01, Vol.260-262, p.183-189

2007

Volltextzugriff (PDF)

Durable control of metastases in an HLA-A2+ patient with refractory melanoma after low-dose radiotherapy in combination with MAGE-A4 T cell therapy: a case report

Melanoma research, 2023-08

2023

Volltextzugriff (PDF)

Abstract 3715: EP-100 syndergizes with paclitaxel in ovarian, breast and prostate cancer cell lines

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (8_Supplement), p.3715-3715

2012

Volltextzugriff (PDF)

GnRH-R-Targeted Lytic Peptide Sensitizes BRCA Wild-type Ovarian Cancer to PARP Inhibition

Molecular cancer therapeutics, 2019-05, Vol.18 (5), p.969-979

2019

Volltextzugriff (PDF)

Abstract 697: Enhanced tumor control and survival in solid tumor models following combined low dose radiotherapy and T cell therapy

Cancer research (Chicago, Ill.), 2024-03, Vol.84 (6_Supplement), p.697-697

2024

Volltextzugriff (PDF)

Inhibition of STAT6 with Antisense Oligonucleotides Enhances the Systemic Antitumor Effects of Radiotherapy and Anti-PD-1 in Metastatic Non-Small Cell Lung Cancer

Cancer immunology research, 2023-04, Vol.11 (4), p.486-500

2023

Volltextzugriff (PDF)

Conjugates of lytic peptides and LHRH or βCG target and cause necrosis of prostate cancers and metastases

Molecular and cellular endocrinology, 2007-04, Vol.269 (1), p.26-33

2007

Volltextzugriff (PDF)

Inhibition of STAT6 with Antisense Oligonucleotides Enhances the Systemic Antitumor Effects of Radiotherapy and Anti-PD1 in Metastatic Non-Small Cell Lung Cancer

Cancer immunology research, 2023-04, Vol.11 (4), p.486-500

2023

Volltextzugriff (PDF)

EP-100 + paclitaxel to overcome taxane resistance in patients with recurrent LHRH-receptor expressing ovarian cancer

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.5582-5582

2015

Volltextzugriff (PDF)

Abstract 2829: Activity of EP-100 in Non-Hodgkin's Lymphoma - synergy in combination

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (8_Supplement), p.2829-2829

2012

Volltextzugriff (PDF)

1 – 25 von 75

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(53)
Mit Volltextzugriff
(67)

Publikationsform

Sprache

Englisch
(75)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(51)
Life Sciences & Biomedicine
(30)
Science & Technology - Other Topics
(22)
Animals
(21)
Nanoscience & Nanotechnology
(21)
Technology
(20)
Engineering
(17)
Engineering, Biomedical
(17)
Humans
(17)
Mice
(17)
Biomedical Applications
(13)
Female
(13)
Biological And Medical Sciences
(11)
Mice, Nude
(11)
Male
(10)
Oncology
(10)
Tumors
(10)
Melitten - Analogs & Derivatives
(8)
Nanofabrication
(8)
Nanotechnology
(8)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Membrane disrupting lytic peptides for cancer treatments

Novel Use of Low-Dose Radiotherapy to Modulate the Tumor Microenvironment of Liver Metastases

Combining a nanoparticle-mediated immunoradiotherapy with dual blockade of LAG3 and TIGIT improves the treatment efficacy in anti-PD1 resistant lung cancer

Inhibition of MER proto-oncogene tyrosine kinase by an antisense oligonucleotide enhances treatment efficacy of immunoradiotherapy

NBTXR3 improves the efficacy of immunoradiotherapy combining nonfucosylated anti-CTLA4 in an anti-PD1 resistant lung cancer model

Nanofabrication Towards Biomedical Applications: Techniques, Tools, Applications, and Impact

Molecular MRI for sensitive and specific detection of lung metastases

LHRH-conjugated magnetic iron oxide nanoparticles for detection of breast cancer metastases

Targeting Breast and Prostate Cancers Through Their Hormone Receptors

Nanoparticle-enhanced proton beam immunoradiotherapy drives immune activation and durable tumor rejection

Abstract LB-303: Novel peptide is synergistic with checkpoint inhibitor antiCTLA4

Abstract 3199: Targeting LHRH-R to improve immune response in ovarian cancer

A multicenter open-label randomized phase II trial of paclitaxel plus EP-100, a novel LHRH receptor-targeted, membrane-disrupting peptide, versus paclitaxel alone for refractory or recurrent ovarian cancer

Enhanced Immunotherapy with LHRH-R Targeted Lytic Peptide in Ovarian Cancer

Abstract 978: Synergistic activity of EP-100 and chemotherapies in cancer cell lines

Destruction of breast cancers and their metastases by lytic peptide conjugates in vitro and in vivo

Durable control of metastases in an HLA-A2+ patient with refractory melanoma after low-dose radiotherapy in combination with MAGE-A4 T cell therapy: a case report

Abstract 3715: EP-100 syndergizes with paclitaxel in ovarian, breast and prostate cancer cell lines

GnRH-R-Targeted Lytic Peptide Sensitizes BRCA Wild-type Ovarian Cancer to PARP Inhibition

Abstract 697: Enhanced tumor control and survival in solid tumor models following combined low dose radiotherapy and T cell therapy

Inhibition of STAT6 with Antisense Oligonucleotides Enhances the Systemic Antitumor Effects of Radiotherapy and Anti-PD-1 in Metastatic Non-Small Cell Lung Cancer

Conjugates of lytic peptides and LHRH or βCG target and cause necrosis of prostate cancers and metastases

Inhibition of STAT6 with Antisense Oligonucleotides Enhances the Systemic Antitumor Effects of Radiotherapy and Anti-PD1 in Metastatic Non-Small Cell Lung Cancer

EP-100 + paclitaxel to overcome taxane resistance in patients with recurrent LHRH-receptor expressing ovarian cancer

Abstract 2829: Activity of EP-100 in Non-Hodgkin's Lymphoma - synergy in combination

Suchergebnisse filtern